Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  plerixafor
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
O6-Benzylguanine-Mediated Tumor Sensitization with Chemoprotected Autologous Stem Cell in Treating Patients with Malignant Gliomas
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Plerixafor and Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-273, NCI-2009-01123, NCT00903968
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Filgrastim with or without Plerixafor for Mobilization and Collection of Progenitor Cells in Patients with Multiple Myeloma Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 12-C-0074, NCI-2013-01533, 120074, P11929, NCT01547806
Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Hematological Malignancies Previously Treated with Donor Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 21
Trial IDs: HAP3R, NCI-2012-00554, NCT01621477
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 201403068, NCI-2014-00870, 14-X057, NCT02098109
Stem Cell Collection with or without Bortezomib in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-IIT-BMT-MM-AutoSCT, NCI-2016-00429, STUDY00002857, NCT02703779
Gene Therapy for Fanconi Anemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2097.00, NCI-2011-00202, NCT01331018
Plerixafor and Bevacizumab in Treating Patients with Recurrent High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-329, NCI-2012-00149, MAMO0909-6, NCT01339039
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma with HIV Infection
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 66
Trial IDs: 2673.00, NCI-2014-02395, 2673, NCT02343666
Plerixafor in Increasing CD34+ Hematopoietic Progenitor Cells in Patients with Sickle Cell Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 65
Trial IDs: 13-229, NCI-2014-02024, NCT02193191
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients with Non-Hodgkin Lymphoma
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 78
Trial IDs: CASE2410, NCI-2011-01281, NCT01408043
Start Over